Overview

Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated. And based on this information, biomarkers for diagnosis, treatment, and prognosis of pancreatic cancer are explored.

Eligibility

Inclusion Criteria:

• Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins
• Patients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule
• Among patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control group

Exclusion Criteria:

• Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form
• If a laboratory test is impossible due to a qualitative problem with the collected blood sample
• Where the collected tissue does not contain tissue of the desired malignant or benign disease